Anjali Bhat

Dr. Anjali Bhat


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Open access
IHines hipolito
ines hipolito
MRMaxwell J.D. Ramstead
Maxwell J.D. Ramstead
LCLaura Convertino
Laura Convertino
ABAnjali Bhat
Anjali Bhat
KFKarl Friston Friston
Karl Friston Friston
TPThomas Parr
Thomas Parr
Recent characterisations of self-organising systems depend upon the presence of a 'Markov blanket': a statistical boundary that mediates the interactions between the inside and outside of a system. We leverage this idea to provide an analysis of partitions in neuronal systems. This is applicable to brain architectures at multiple scales, enabling partitions into single neurons, brain regions, and brain-wide networks. This treatment is based upon the canonical micro-circuitry used in empirical studies of effective connectivity, so as to speak directly to practical applications. The notion of effective connectivity depends upon the dynamic coupling between functional units, whose form recapitulates that of a Markov blanket at each level of analysis. The nuance afforded by partitioning neural systems in this way highlights certain limitations of 'modular' perspectives of brain function that only consider a single level of description.

30 April 2021 in Biology & Philosophy
Verified
Journal Article
Open access
PDF file
ABAnjali Bhat
Anjali Bhat
TPThomas Parr
Thomas Parr
MRMaxwell Ramstead
Maxwell Ramstead
KFKarl Friston Friston
Karl Friston Friston
There is a steadily growing literature on the role of the immune system in psychiatric disorders. So far, these advances have largely taken the form of correlations between specific aspects of inflammation (e.g. blood plasma levels of inflammatory markers, genetic mutations in immune pathways, viral or bacterial infection) with the development of neuropsychiatric conditions such as autism, bipolar disorder, schizophrenia and depression. A fundamental question remains open: why are psychiatric disorders and immune responses intertwined? To address this would require a step back from a historical mind–body dualism that has created such a dichotomy. We propose three contributions of active inference when addressing this question: translation, unification, and simulation. To illustrate these contributions, we consider the following questions. Is there an immunological analogue of sensory attenuation? Is there a common generative model that the brain and immune system jointly optimise? Can the immune response and psychiatric illness both be explained in terms of self-organising systems responding to threatening stimuli in their external environment, whether those stimuli happen to be pathogens, predators, or people? Does false inference at an immunological level alter the message passing at a psychological level (or vice versa) through a principled exchange between the two systems?

3 November 2021 in Genes
Verified
Journal Article
Open access
PDF file
IAIsabelle Austin-Zimmerman
Isabelle Austin-Zimmerman
MWMarta Wronska
Marta Wronska
BWBaihan Wang
Baihan Wang
HIHaritz Irizar
Haritz Irizar
JTJohan H. Thygesen
Johan H. Thygesen
EBElvira Bramon
Elvira Bramon
CYP2D6 and CYP2C19 enzymes are essential in the metabolism of antidepressants and antipsychotics. Genetic variation in these genes may increase risk of adverse drug reactions. Antidepressants and antipsychotics have previously been associated with risk of diabetes. We examined whether individual genetic differences in CYP2D6 and CYP2C19 contribute to these effects. We identified 31,579 individuals taking antidepressants and 2699 taking antipsychotics within UK Biobank. Participants were classified as poor, intermediate, or normal metabolizers of CYP2D6, and as poor, intermediate, normal, rapid, or ultra-rapid metabolizers of CYP2C19. Risk of diabetes mellitus represented by HbA1c level was examined in relation to the metabolic phenotypes. CYP2D6 poor metabolizers taking paroxetine had higher Hb1Ac than normal metabolizers (mean difference: 2.29 mmol/mol; p < 0.001). Among participants with diabetes who were taking venlafaxine, CYP2D6 poor metabolizers had higher HbA1c levels compared to normal metabolizers (mean differences: 10.15 mmol/mol; p < 0.001. Among participants with diabetes who were taking fluoxetine, CYP2D6 intermediate metabolizers and decreased HbA1c, compared to normal metabolizers (mean difference −7.74 mmol/mol; p = 0.017). We did not observe any relationship between CYP2D6 or CYP2C19 metabolic status and HbA1c levels in participants taking antipsychotic medication. Our results indicate that the impact of genetic variation in CYP2D6 differs depending on diabetes status. Although our findings support existing clinical guidelines, further research is essential to inform pharmacogenetic testing for people taking antidepressants and antipsychotics.

27 July 2020 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
JTJohan H. Thygesen
Johan H. Thygesen
APAmelia Presman
Amelia Presman
JHJasmine Harju-Seppänen
Jasmine Harju-Seppänen
HIHaritz Irizar
Haritz Irizar
RJRebecca Jones
Rebecca Jones
EBElvira Bramon
Elvira Bramon
The burden of large and rare copy number genetic variants (CNVs) as well as certain specific CNVs increase the risk of developing schizophrenia. Several cognitive measures are purported schizophrenia endophenotypes and may represent an intermediate point between genetics and the illness. This paper investigates the influence of CNVs on cognition. We conducted a systematic review and meta-analysis of the literature exploring the effect of CNV burden on general intelligence. We included ten primary studies with a total of 18,847 participants and found no evidence of association. In a new psychosis family study, we investigated the effects of CNVs on specific cognitive abilities. We examined the burden of large and rare CNVs (>200 kb, <1% MAF) as well as known schizophrenia-associated CNVs in patients with psychotic disorders, their unaffected relatives and controls (N = 3428) from the Psychosis Endophenotypes International Consortium (PEIC). The carriers of specific schizophrenia-associated CNVs showed poorer performance than non-carriers in immediate (P = 0.0036) and delayed (P = 0.0115) verbal recall. We found suggestive evidence that carriers of schizophrenia-associated CNVs had poorer block design performance (P = 0.0307). We do not find any association between CNV burden and cognition. Our findings show that the known high-risk CNVs are not only associated with schizophrenia and other neurodevelopmental disorders, but are also a contributing factor to impairment in cognitive domains such as memory and perceptual reasoning, and act as intermediate biomarkers of disease risk.

1 March 2021 in Cell Reports
Verified
Journal Article
Open access
ABAnjali Bhat
Anjali Bhat
HIHaritz Irizar
Haritz Irizar
JTJohan Hilge Thygesen
Johan Hilge Thygesen
KKKaroline Kuchenbaecker
Karoline Kuchenbaecker
OPOliver Pain
Oliver Pain
EBElvira Bramon
Elvira Bramon
Mismatch negativity (MMN) is a differential electrophysiological response measuring cortical adaptability to unpredictable stimuli. MMN is consistently attenuated in patients with psychosis. However, the genetics of MMN are uncharted, limiting the validation of MMN as a psychosis endophenotype. Here, we perform a transcriptome-wide association study of 728 individuals, which reveals 2 genes (FAM89A and ENGASE) whose expression in cortical tissues is associated with MMN. Enrichment analyses of neurodevelopmental expression signatures show that genes associated with MMN tend to be overexpressed in the frontal cortex during prenatal development but are significantly downregulated in adulthood. Endophenotype ranking value calculations comparing MMN and three other candidate psychosis endophenotypes (lateral ventricular volume and two auditory-verbal learning measures) find MMN to be considerably superior. These results yield promising insights into sensory processing in the cortex and endorse the notion of MMN as a psychosis endophenotype.

15 June 2022 in Brain, Behavior, and Immunity
Verified
Journal Article
Open access
ABAnjali Bhat
Anjali Bhat
HIHaritz Irizar
Haritz Irizar
ACAmalie C.M. Couch
Amalie C.M. Couch
PRPooja Raval
Pooja Raval
RDRodrigo R.R. Duarte
Rodrigo R.R. Duarte
DSDeepak P. Srivastava
Deepak P. Srivastava
• Human cortical NPCs show a significant transcriptional response to IFNγ treatment. • This response is attenuated in cortical NPCs from schizophrenia patients. • The abnormal transcriptional response is driven by mitochondrial and synaptic genes. • Cortical NPCs do not show significant transcriptional response to IL-1β treatment.